Adverse events: psychological disorders · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ psychiatric disorders ‐ total psychiatric disorders ( compared with placebo (low certainty).
1 finding from 1 review
Adverse event: gastrointestinal disorders at 1‐month (with actual · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ gastrointestinal disorders ‐ total gastrointestinal… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: 1. General ‐ overall number of events · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ general ‐ total general adverse events ( compared with placebo (low certainty).
1 finding from 1 review
Specific behaviour ‐ agitation
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Psychosis ‐ presented in units of NPI‐NH P (higher is worse)d ‐ 3364 persons in 12 RCTs of 3 to 12 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Response for psychosis ‐ as defined by authors of RCTs ‐ 1958 persons in 7 RCTs of 3 to 12 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Somnolence
1 finding from 1 review
no estimate extracted
Studies not reported
High
Death ‐ 5032 persons in 17 RCTs of 3 to 12 weeks ___________________________________________
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Response for agitation ‐ as defined by authors of RCTs ‐ 1303 persons in 4 RCTs of 3 to 12 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Psychosis ‐ presented in units of NPI‐NH P (higher is worse)d ‐ 3364 persons in 12 RCTs of 3 to 12 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Response for psychosis ‐ as defined by authors of RCTs ‐ 1958 persons in 7 RCTs of 3 to 12 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms
1 finding from 1 review
no estimate extracted
Studies not reported
High
Somnolence
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Death ‐ 5032 persons in 17 RCTs of 3 to 12 weeks ___________________________________________
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Specific behaviour ‐ agitation
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Response for agitation ‐ as defined by authors of RCTs ‐ 1303 persons in 4 RCTs of 3 to 12 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Cognitive function · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Cognitive function · vascular dementia and other vascular cognitive impairments
1 finding from 1 review